Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Investor Presentation (March 2023)
28 slides from Arbutus Biopharma's investor presentation, Mar 2, 2023
Slide 1: Corporate Presentation
NASDAQ: ABUS www.arbutusbio.com March 2, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc.
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking statements fo
Slide 3: Our Strategy
Our Strategy Leverage the proven track record of success established with our team's expertise in understanding and treating viral infections by discovering and developing a broad, differentiated pipeline of therapies targeting chronic HBV, COVID - 19, and future coronavirus outbreaks. Develop a com
Slide 4: Investment Highlights
Investment Highlights Strong financial position Indications with significant unmet medical need & large market opportunities Patented LNP technology Broad portfolio of internally discovered assets with distinct MOAs Lead HBV compound – AB - 729 RNAi therapeutic in multiple Phase 2a combination clini
Slide 5: Broad Pipeline
Broad Pipeline HBV AB - 729 - 001 single - ascending dose / multiple - ascending dose RNAi Therapeutic AB - 729 AB - 729 - 201 Combo trial (AB - 729 + Peg - IFNa - 2a + NA) AB - 729 - 202 Combo trial (AB - 729 + vaccine + NA ) PD - L1 Inhibitor (oral) AB - 101 RNA destabilizer (oral) AB - 161 COVID
Slide 6: HBV Overview
HBV Overview Life - threatening liver infection caused by hepatitis B virus (HBV) Transmitted through body fluids and from mother to child Long - term chronic infection ( cHBV ) leads to higher risk of cirrhosis and/or liver cancer Cause & Symptoms Diagnosis HBsAg detection Additional biomarkers nec
Slide 7: HBV Presents a Significant Unmet Medical Need
Africa 60M E Mediterranean 21M SE Asia 39M W Pacific 115M EU 15M Americas 7M ~820k people die every year as a consequence despite the availability of effective vaccines and antivirals. people are chronically infected with HBV, globally. >290M >290M Chronic HBV Sources: https://www.who.int/news - roo
Slide 8: 3-Pronged Approach to Therapeutic Success
Suppress Reduce Boost Viral DNA and cccDNA Pool Viral Antigen - HBsAg Host Immune System Leading to an HBV Cure 3 - Pronged Approach to Therapeutic Success Therapeutic success will require a combination of agents with complementary MOAs. Suppress HBV DNA Reduce viral antigens Boost host immune respo
Slide 9: RNAi Therapeutic GalNAc-conjugate delivery technology
Proprietary GalNAc - conjugate delivery technology provides liver targeting and enables subcutaneous dosing Single trigger RNAi agent targeting all HBV transcripts Inhibits HBV replication and lowers all HBV antigens Pan - genotypic activity across HBV genotypes Demonstrated complementarity with oth
Slide 10: Phase 1a/1b Clinical Trial
AB - 729 - 001 Phase 1a/1b Clinical Trial HBeAg : HBV E antigen | TDF: tenofovir disoproxil fumarate Part 3: Multiple Ascending Dose in cHBV Patients E: 60mg Q4W HBV DNA - F: 60mg Q8W HBV DNA - G: 90mg Q8W + TDF HBV DNA+ I: 90mg Q8W HBV DNA - J: 90mg Q12W HBV DNA - K: 90mg Q8W HBV DNA - , HBeAg + on
Slide 11: Robust HBsAg Declines Irrespective of Dose, Schedule, HBeAg or HBV DNA Status
Robust HBsAg Declines Irrespective of Dose, Dosing Schedule, HBeAg or HBV DNA Status Mean (SE) Baseline and Δ log 10 HBsAg by Visit Data shown as mean (SE) log 10 IU/mL; Last AB - 729 dose Cohort E: Week 44, Cohorts F, I, G, K: Week 40, Cohort J: Week 36; HBsAg Assay LLOQ = 0.07 IU/mL; *N=6; # N=5 1
Slide 12: Robust & Sustained HBsAg Declines While On- or Off-Treatment
Data presented at EASL 2022 and AASLD 2022 12 Change in HBsAg vs time AB - 729 - 001: Robust & Sustained HBsAg Declines While On - or Off - Treatment with AB - 729 33 of 41 patients had HBsAg < 100 IU/mL at some point during the trial 1 patient in Cohort E (baseline HBsAg = 583.5 IU/mL) who qualifie
Slide 13: Meaningful Suppression of HBV Biomarkers While Off-Treatment
AB - 729 - 001: AB - 729 Shows Meaningful Suppression of HBV Biomarkers in cHBV Patients While Off - Treatment HBV DNA has transiently increased in some patients and subsequently decreased with no intervention 13 Data presented at AASLD 2022 Pt. 46 Pt. 51 Pt. 52 Pt. 53* Pt. 56 Pt. 58** Pt. 59 Pt. 60
Slide 14: Treatment Reactivates HBV Specific Immunity in Some Patients
AB - 729 - 001: Treatment with AB - 729 Reactivates HBV Specific Immunity in Some Patients 14 0 4 812162024283236404448525660 0 1 2 3 4 5 0 20 40 60 H B s A g ( L o g 1 0 I U / m L ) Patient 43 60 mg Q4W 0 4 8 1216202428323640444852 0 1 2 3 4 0 10 20 30 40 50 60 H B s A g ( L o g 1 0 I U / m L ) Pat
Slide 15: Safety Summary
AB - 729 - 001 Safety Summary AB - 729 is generally safe and well - tolerated after repeat dosing for up to 48 weeks No treatment - related SAEs or discontinuations due to AEs No treatment - related Grade 3 or 4 AEs No treatment - related Grade 3 or 4 laboratory abnormalities • Grade 1 and Grade 2 A
Slide 16: Clinical Trial Key Takeaways
AB - 729 - 001 Clinical Trial Key Takeaways AB - 729 provided robust and comparable HBsAg declines regardless of dose, dosing interval, HBeAg or DNA status ~75% (26 of 34) patients had HBsAg levels <100 at some point during the trial 50% (16 of 32) patients maintained HBsAg <100 IU/mL for 24 weeks a
Slide 17: Phase 2a POC Clinical Trial with Peg-IFNα-2a (201)
Phase 2a POC Clinical Trial AB - 729 in combination with ongoing NA therapy and short courses of Peg - IFN α - 2 a in cHBV patients AB - 729 - 201: Follow - up (24 - weeks) AB - 729 + NA + IFN (n=12) NA + IFN (n=12) AB - 729+NA+IFN (n=8) NA + IFN (n=8) AB - 729 + NA (60mg Q8W) n=40 HBeAg - Randomize
Slide 18: Phase 2a POC Clinical Trial with VTP-300 (202)
Phase 2a POC Clinical Trial POC Phase 2a clinical trial evaluating AB - 729 in combination with Vaccitech’s immunotherapeutic, VTP - 300, and a NA AB - 729 - 202: Primary objective: evaluate safety and reactogenicity of AB - 729 followed by VTP - 300 or placebo At week 48 all participants who are el
Slide 19: Strategic Collaboration with Qilu Pharmaceutical
Strategic Collaboration Exclusive Licensing* and Strategic Partnership Develop, manufacture and commercialize AB - 729 in mainland China, Hong Kong, Macau and Taiwan AB - 729 $40M Upfront payment (received in 2022) $15M Equity investment (received in 2022) Up to $245M Commercialization and milestone
Slide 20: AB-101: Oral PD-L1 Inhibitor for HBV Immune Reactivation
AB - 101: Oral PD - L1 Inhibitor for HBV Immune Reactivation PD - 1: Programmed death ligand protein | Abs: Antibodies AB - 101 is advancing into Phase 1 clinical trial in 1H 2023 Rationale • HBV immune tolerance is a critical driver of cHBV infection • PD - 1:PD - L1 checkpoint axis plays a key rol
Slide 21: AB-101: Small-Molecule Oral PD-L1 Inhibitor for HBV
AB - 101: Small - Molecule Oral PD - L1 Inhibitor for HBV AB - 101 is highly potent with demonstrated activity against PD - L1 in cells from chronic HBV patients AB - 101 reduces PD - L1 on the surface of human primary myeloid cells AB - 101 reinvigorates HBV - specific cHBV patient T - cells Data p
Slide 22: AB-161: Next Generation Oral RNA Destabilizer
AB - 161: Next Generation Oral RNA Destabilizer AB - 161 is advancing into Phase 1 clinical trial in 1H 2023 Next generation small molecule anticipated to circumvent non - clinical safety findings with first generation molecule Offers a novel mechanism of action to reduce HBsAg, other viral proteins
Slide 23: AB-161 Reduces HBsAg in AAV-HBV Mouse Model
AB - 161 Reduces HBsAg in AAV - HBV Mouse Model 23 Fraction Unbound Concentrations (C 24h ) 0 2 4 6 8 10 12 14 1 10 100 Days S e r u m H B s A g ( % B a s e l i n e ) Vehicle AB-161 0.3 mg/kg AB-161 1 mg/kg AB-161 10 mg/kg AB-161 30 mg/kg [AB - 161] free : plasma [AB - 161] free : liver AAV - HBV mo
Slide 24: Coronavirus Program Overview
Coronavirus Program Overview 1 https://www.healthdata.org/special - analysis/ estimation - excess - mortality - due - covid - 19 - and - scalars - reported - covid - 19 - deaths Coronavirus Infections, such as COVID - 19 caused by SARS - CoV - 2 Spreads through breathing out droplets and small parti
Slide 25: Coronavirus Strategy
Viral Polymerase nucleos (t)ides COVID - 19 Virus nsp12 Viral Protease de novo design COVID - 19 Virus nsp5 / M pro Leveraging our proven expertise and capabilities in antiviral drug discovery and development Coronavirus Strategy Arbutus Strategy nsp5 protease & nsp12 polymerase essential enzymes fo
Slide 26: AB-343: M PRO Coronavirus Candidate
AB - 343: M PRO Coronavirus Candidate AB - 343 is currently in IND - enabling studies • Highly potent (IC 50 < 8nM) • Equipotent against all known COVID - 19 variants • Robust activity against M pro resistant variants • Highly selective for coronavirus M pro vs human proteases • Clean cell toxicity
Slide 27: 2023 Key Milestones
2023 Key Milestones Cash balance * of $184M as of December 31, 2022, cash runway into Q4 2024; 2023 net cash burn of between $95 and $100M *Consists of cash, cash equivalents and marketable securities 27 Milestone Anticipated Timing 2023 AB - 729: Dose f irst patient in the AB - 729+VTP - 300+Nivo a
Slide 28: Thank You
Thank You © 2023 Arbutus Biopharma, Inc.
Arbutus Biopharma — Investor Presentation (March 2023) on 6ix